Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).

被引：0
|
作者：
Thein, Wai Lin
Tun, Aung
Thein, Kyaw Zin
Guevara, Elizabeth
机构：
[1] Univ Med, Brooklyn, NY USA
[2] Brooklyn Hosp Ctr, Brooklyn, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
    Tun, Aung
    Thein, Wai Lin
    Elfiky, Aymen
    Gasperino, James
    Guevara, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [2] Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
    Mogollon-Duffo, F.
    Sultan, A.
    Swarup, S.
    Jahan, N.
    Tun, A. M.
    Htut, T. Win
    Naing, T. W.
    Naing, P. T.
    Myat, Y. Mon
    Hardwicke, F.
    Rehman, S.
    Tijani, L.
    D'Cunha, N.
    Thein, K. Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 621 - 621
  • [3] Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Tun, Aung Myint
    Thein, Kyaw Zin
    LinThein, Wai
    Guevara, Elizabeth
    FUTURE SCIENCE OA, 2019, 5 (09):
  • [4] Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
    Dafni, Urania
    Tsourti, Zoi
    Vervita, Katerina
    Peters, Solange
    LUNG CANCER, 2019, 134 : 127 - 140
  • [5] Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Chen, Yuqiao
    Zhou, Yuan
    Tang, Lu
    Peng, Xiong
    Jiang, Hong
    Wang, Guo
    Zhuang, Wei
    JOURNAL OF CANCER, 2019, 10 (25): : 6261 - 6268
  • [6] Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Metro, Giulio
    Di Maio, Massimo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
    Thein, K. Z.
    Mogollon-Duffo, F.
    Swarup, S.
    Sultan, A.
    Yendala, R.
    Jahan, N.
    Quirch, M.
    Ball, S.
    Htut, T. Win
    D'Cunha, N.
    Rehman, S.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
    Khan, Muhammad
    Lin, Jie
    Liao, Guixiang
    Tian, Yunhong
    Liang, Yingying
    Li, Rong
    Liu, Mengzhong
    Yuan, Yawei
    MEDICINE, 2018, 97 (33)
  • [9] Study protocol: Systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer
    DeLozier A.M.
    Brown J.
    Natanegara F.
    Zhao L.
    Cui Z.L.
    Able S.L.
    Bowman L.
    Treat J.
    Hess L.M.
    Systematic Reviews, 3 (1)
  • [10] The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials
    Abdelazeem, Basel
    Abbas, Kirellos Said
    Labieb, Fatma
    Arida, Abdul Karim
    El-Shahat, Nahla Ahmed
    Shehata, Joseph
    Kandah, Emad
    Malik, Bilal
    Akanbi, Maxwell
    Rafae, Abdul
    Wahab, Ahsan
    Ehsan, Hamid
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1127 - 1140
12345